Fresenius Lost Chance To Appeal Antitrust Suit, 3rd Circ. Told
Drugmaker Par Pharmaceutical urged the Third Circuit to deny health care company Fresenius Kabi USA's petition for a panel to rehear its antitrust case alleging Par delayed Fresenius from marketing a...To view the full article, register now.
Already a subscriber? Click here to view full article